Garret M Hampton
Overview
Explore the profile of Garret M Hampton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3073
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson T, Yu J, Lu X, Spoerke J, Xiao Y, OBrien C, et al.
NPJ Breast Cancer
. 2017 Jul;
2:16022.
PMID: 28721382
Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular landscape of high-risk...
2.
Kim D, Choi Y, Ireland J, Foreman O, Tam R, Patel R, et al.
PLoS One
. 2016 Nov;
11(11):e0165856.
PMID: 27846280
In the age of personalized medicine stratifying tumors into molecularly defined subtypes associated with distinctive clinical behaviors and predictable responses to therapies holds tremendous value. Towards this end, we developed...
3.
Spoerke J, Gendreau S, Walter K, Qiu J, Wilson T, Savage H, et al.
Nat Commun
. 2016 May;
7:11579.
PMID: 27174596
Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in...
4.
Nakanishi Y, Walter K, Spoerke J, OBrien C, Huw L, Hampton G, et al.
Cancer Res
. 2016 Jan;
76(5):1193-203.
PMID: 26759240
Activation of the PI3K pathway occurs commonly in a wide variety of cancers. Experience with other successful targeted agents suggests that clinical resistance is likely to arise and may reduce...
5.
Wilson T, Xiao Y, Spoerke J, Fridlyand J, Koeppen H, Fuentes E, et al.
Breast Cancer Res Treat
. 2014 Oct;
148(2):315-25.
PMID: 25338319
Breast cancers are categorized into three subtypes based on protein expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/ERBB2). Patients enroll onto experimental clinical...
6.
Zhang L, Chen L, Sah S, Latham G, Patel R, Song Q, et al.
Oncologist
. 2014 Mar;
19(4):336-43.
PMID: 24664487
Purpose: The success of precision oncology relies on accurate and sensitive molecular profiling. The Ion AmpliSeq Cancer Panel, a targeted enrichment method for next-generation sequencing (NGS) using the Ion Torrent...
7.
Walter K, Holcomb T, Januario T, Yauch R, Du P, Bourgon R, et al.
Epigenomics
. 2014 Mar;
6(1):59-72.
PMID: 24579947
Lung cancer remains the primary cause of cancer-related deaths worldwide. Improved tools for early detection and therapeutic stratification would be expected to increase the survival rate for this disease. Alterations...
8.
Bourgon R, Lu S, Yan Y, Lackner M, Wang W, Weigman V, et al.
Clin Cancer Res
. 2014 Feb;
20(8):2080-91.
PMID: 24573554
Purpose: Tailoring cancer treatment to tumor molecular characteristics promises to make personalized medicine a reality. However, reliable genetic profiling of archived clinical specimens has been hindered by limited sensitivity and...
9.
Schleifman E, Desai R, Spoerke J, Xiao Y, Wong C, Abbas I, et al.
PLoS One
. 2014 Feb;
9(2):e88401.
PMID: 24520381
Patients with newly diagnosed, early stage estrogen receptor positive (ER+) breast cancer often show disease free survival in excess of five years following surgery and systemic adjuvant therapy. An important...
10.
Penuel E, Li C, Parab V, Burton L, Cowan K, Merchant M, et al.
Mol Cancer Ther
. 2013 Mar;
12(6):1122-30.
PMID: 23536720
The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in...